Tiziana Life Sciences Ltd (NASDAQ:TLSA) said CEO Ivor Elrifi has increased his stake in the company by purchasing 667,000 common shares on the Nasdaq at US$1 per share. The purchase brings his total holdings to 4,472,261 shares.
Tiziana is developing immunomodulation therapies, led by intranasal foralumab, a fully human anti-CD3 monoclonal antibody.